Amylyx Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Amylyx Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 4 completed early-phase tilt top decile by trial count

Amylyx Pharmaceuticals: 9 sponsored US clinical trials, 1 recruiting.

Amylyx Pharmaceuticals sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Amyotrophic Lateral Sclerosis, with 3 trials.

Top-decile sponsor footprint

Amylyx Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 1

AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

NCT06665165
ACTIVE NOT RECRUITING Phase 3

Avexitide for Treatment of Post-Bariatric Hypoglycemia

NCT06747468
ACTIVE NOT RECRUITING Phase 2

AMX0035 and Progressive Supranuclear Palsy

NCT06122662
ACTIVE NOT RECRUITING Phase 2

AMX0035 in Adult Patients With Wolfram Syndrome

NCT05676034
ACTIVE NOT RECRUITING Phase 3

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

NCT05021536
COMPLETED Phase 2

A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT04516096
COMPLETED Phase 2

Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

NCT03533257
COMPLETED Phase 2

Open Label Extension Study of AMX0035 in Patients With ALS

NCT03488524
COMPLETED Phase 2

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03127514

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 6
Phase 3 2

Therapeutic Areas

Amyotrophic Lateral Sclerosis 3
ALS 2
Atypical Parkinsonism 1
Wolfram Syndrome 1
PSP 1
Neurodegenerative Diseases 1
Post-Bariatric Hypoglycemia 1
Progressive Supranuclear Palsy 1
Alzheimer Disease 1

What is open in the Amylyx Pharmaceuticals pipeline

1 recruiting of 9 indexed (11% open); 4 completed (44%).

Phase mix: 2 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Amyotrophic Lateral Sclerosis (3 trials), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Amylyx Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Amylyx Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share Amylyx Pharmaceuticals4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAprea Therapeutics
Amylyx Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Amylyx Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Amylyx Pharmaceuticals page

9 registered trials is a research-attention snapshot, not an endorsement of Amylyx Pharmaceuticals or any single study.

  • 1 of Amylyx Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Amyotrophic Lateral Sclerosis is the condition Amylyx Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Amyotrophic Lateral Sclerosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Amylyx Pharmaceuticals pipeline card: 9 registered trials from official public datasets.Report a data error.